Emtora Data in Spotlight at 2024 Digestive Disease Week

Emtora Biosciences, Inc., a San Antonio-based biotech firm, has announced the acceptance of an abstract for oral presentation at the upcoming Digestive Disease Week Annual Meeting. This prestigious event gathers professionals in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery worldwide. Dr. Carol Burke, MD, will present the 6-month primary endpoint data of Emtora’s eRapaTM in patients with Familial Adenomatous Polyposis (FAP), a genetic condition characterized by precancerous polyps in the gastrointestinal tract. FAP lacks an approved chemo-preventive treatment, and eRapaTM, a potent mTOR inhibitor, shows promise in reducing polyp progression. The Phase 2 trial was funded by a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Emtora plans to initiate a Phase 3 trial soon. Details of the presentation are provided below.

Presentation Title: Phase IIA Trial of Encapsulated Rapamycin (eRapa) in Patients with Familial Adenomatous Polyposis to Reduce Intestinal Polyp Burden: 6-Month Interim Results Session: Chemoprevention for GI Cancers: Drugs and/or Bugs Abstract Number: 4041480 Embargo Date: May 21, 2024 Embargo Time: 12:01 a.m. EST Presentation Date: May 21, 2024 Time: 2:00 PM – 2:15 PM EST Location: 146AB Presenter: Carol Burke, MD, Director of Hereditary Polyposis, Sanford R. Weiss MD Center for Colorectal Neoplasia, Cleveland Clinic

About Digestive Disease Week (DDW): DDW is the largest international gathering of professionals in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The event showcases the latest advances in GI research, medicine, and technology, featuring over 4,400 abstracts and hundreds of lectures.

About Emtora Biosciences: Emtora is a clinical-stage biopharmaceutical company developing eRapaTM, an encapsulated formulation of rapamycin, for rare genetic diseases and cancer treatment. The lead indication is Familial Adenomatous Polyposis. eRapaTM offers advantages over rapamycin, including targeted delivery, reduced toxicity, and improved tolerability.

About Cancer Prevention and Research Institute of Texas (CPRIT): CPRIT leads Texas’ fight against cancer, investing in research, prevention, and product development. It has awarded over $3 billion in grants to Texas institutions and recruited distinguished researchers.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter